STAT+: In a ‘baffling’ disappointment, BridgeBio’s heart drug misses primary goal in pivotal study
A treatment developed by BridgeBio for an increasingly common heart disease missed its primary endpoint in a closely watched trial, the company said Monday, derailing its plans and prolonging the development of what experts considered a promising new drug.
Patients treated with the drug, called acoramidis, performed no better than those on a placebo on a test of how far they could walk over the course of six minutes. BridgeBio enrolled about 600 patients with ATTR-CM, a progressive heart disease. After 12 months, patients who got acoramidis could walk nine meters fewer, and patients on placebo walked seven minutes fewer.
Continue to STAT+ to read the full story…
